

LIST OF FIGURES

Figure 1: Clinical development of medicines.....	13
Figure 2: Scope of Pharmacovigilance.....	15
Figure 3: Pharmacovigilance framework.....	15
Figure 4: AEFI fields added in Vigiflow software.....	108
Figure 5: Causality of AEFI fields added in Vigiflow software.....	109
Figure 6: Distribution of AEs observed for anti-diabetic treatment	118
Figure 7: AEs observed in patients on specific anti-diabetic drugs	119
Figure 8: Informative poster about hypoglycemia.....	123
Figure 9: Educational DVD and a book of Visceral Leishmaniasis.....	124
Figure 10: Nevirapine induced rash.....	133
Figure 11: S J syndrome due to nevirapine.....	134
Figure 12: Nail pigmentation due to zidovudine.....	134